About P-selectin glycoprotein ligand 1
P-selectin glycoprotein ligand 1 (SELPLG) is a protein
from Homo sapiens identified by UniProt accession
Q14242, 412 residues long.
MolForge cross-references it against 0 known binders and
478 disease associations.
Target properties
| Protein name | P-selectin glycoprotein ligand 1 |
| UniProt accession | Q14242 |
| Gene | SELPLG |
| Organism | Homo sapiens |
| Length | 412 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (478)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.31
- glioblastoma multiforme · score 0.19
- breast adenocarcinoma · score 0.18
- intraocular pressure measurement · score 0.17
- optic disc size measurement · score 0.14
- inflammatory bowel disease · score 0.13
- reticulocyte count · score 0.12
- reticulocyte measurement · score 0.11
- neoplasm · score 0.11
- low grade glioma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14242-F1 | alphafold | PREDICTED | 50.37 | — |
Amino-acid sequence (412 residues)
MPLQLLLLLI LLGPGNSLQL WDTWADEAEK ALGPLLARDR RQATEYEYLD YDFLPETEPP EMLRNSTDTT PLTGPGTPES TTVEPAARRS TGLDAGGAVT ELTTELANMG NLSTDSAAME IQTTQPAATE AQTTQPVPTE AQTTPLAATE AQTTRLTATE AQTTPLAATE AQTTPPAATE AQTTQPTGLE AQTTAPAAME AQTTAPAAME AQTTPPAAME AQTTQTTAME AQTTAPEATE AQTTQPTATE AQTTPLAAME ALSTEPSATE ALSMEPTTKR GLFIPFSVSS VTHKGIPMAA SNLSVNYPVG APDHISVKQC LLAILILALV ATIFFVCTVV LAVRLSRKGH MYPVRNYSPT EMVCISSLLP DGGEGPSATA NGGLSKAKSP GLTPEPREDR EGDDLTLHSF LP
Explore P-selectin glycoprotein ligand 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets